Recapitulation/NN
of/IN
Candidate/NN
Systemic/JJ
Lupus/NN
Erythematosus-Associated/JJ
Variants/NNS
in/IN
Koreans/NNS
./.
====================
Systemic/JJ
lupus/NN
erythematosus/NN
(/(
SLE/NN
)/)
is/VBZ
a/DT
chronic/JJ
autoimmune/JJ
disease/NN
that/DT
affects/VBZ
multiple/JJ
organ/NN
systems/NNS
./.
====================
Although/IN
the/DT
etiology/NN
of/IN
SLE/NN
remains/VBZ
unclear/JJ
,/,
it/PRP
is/VBZ
widely/RB
accepted/VBN
that/IN
genetic/JJ
factors/NNS
could/MD
be/VB
involved/VBN
in/IN
its/PRP$
pathogenesis/NN
./.
====================
A/DT
number/NN
of/IN
genome-wide/NN
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
have/VBP
identified/VBN
novel/JJ
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
associated/VBN
with/IN
the/DT
risk/NN
of/IN
SLE/NN
in/IN
diverse/JJ
populations/NNS
./.
====================
However/RB
,/,
not/RB
all/DT
the/DT
SNP/NN
candidates/NNS
identified/VBN
from/IN
non-Asian/JJ
populations/NNS
have/VBP
been/VBN
validated/VBN
in/IN
Koreans/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
aimed/VBD
to/TO
replicate/VB
the/DT
SNPs/NNS
that/DT
were/VBD
recently/RB
discovered/VBN
in/IN
the/DT
GWAS/NN
;/:
these/DT
SNPs/NNS
have/VBP
not/RB
been/VBN
validated/VBN
in/IN
Koreans/NNS
or/CC
have/VBP
only/RB
been/VBN
replicated/VBN
in/IN
Koreans/NNS
with/IN
an/DT
insufficient/JJ
sample/JJ
size/NN
to/TO
conclude/VB
any/DT
association/NN
./.
====================
For/IN
this/DT
,/,
we/PRP
selected/VBD
five/CD
SNPs/NNS
(/(
rs1801274/NN
in/IN
FCGR2A/NN
and/CC
rs2286672/NN
in/IN
PLD2/NN
,/,
rs887369/NN
in/IN
CXorf21/NN
,/,
rs9782955/NN
in/IN
LYST/NN
,/,
and/CC
rs3794060/NN
in/IN
NADSYN1/NN
)/)
./.
====================
Through/IN
the/DT
replication/NN
study/NN
with/IN
656/CD
cases/NNS
and/CC
622/CD
controls/NNS
,/,
rs1801274/NN
in/IN
FCGR2A/NN
was/VBD
found/VBN
to/TO
be/VB
significantly/RB
associated/VBN
with/IN
SLE/NN
in/IN
Koreans/NNS
(/(
odds/NNS
ratio/NN
,/,
1.26/CD
,/,
95/CD
%/NN
confidence/NN
interval/JJ
,/,
1.06/CD
to/TO
1.50/CD
;/:
p/NN
=/JJ
0.01/CD
in/IN
allelic/JJ
model/NN
)/)
./.
====================
This/DT
association/NN
was/VBD
also/RB
significant/JJ
in/IN
two/CD
other/JJ
models/NNS
(/(
dominant/JJ
and/CC
recessive/JJ
)/)
./.
====================
The/DT
other/JJ
four/CD
SNPs/NNS
did/VBD
not/RB
show/VB
a/DT
significant/JJ
association/NN
./.
====================
Our/PRP$
data/NNS
support/VBP
that/DT
FCGR/NN
polymorphisms/NNS
play/VBP
important/JJ
roles/NNS
in/IN
the/DT
susceptibility/NN
to/TO
SLE/NN
in/IN
diverse/JJ
populations/NNS
,/,
including/VBG
Koreans/NNS
./.
====================
Systemic/JJ
lupus/NN
erythematosus/NN
(/(
SLE/NN
)/)
is/VBZ
a/DT
chronic/JJ
heterogeneous/JJ
systemic/JJ
autoimmune/JJ
disease/NN
that/DT
can/MD
,/,
in/IN
principle/JJ
,/,
affect/VBP
any/DT
kind/JJ
of/IN
body/NN
organ/NN
or/CC
cell/NN
,/,
primarily/RB
in/IN
young/JJ
women/NNS
[/(
1/CD
]/)
./.
====================
In/IN
SLE/NN
,/,
altered/JJ
immune/JJ
responses/NNS
may/MD
stimulate/VB
the/DT
production/NN
of/IN
autoantibodies/NNS
and/CC
immune/JJ
complex/NN
deposits/VBZ
in/IN
body/NN
organs/NNS
,/,
resulting/VBG
in/IN
organ/NN
damage/NN
[/(
2/CD
]/)
./.
====================
Like/IN
other/JJ
autoimmune/JJ
diseases/NNS
,/,
SLE/NN
has/VBZ
a/DT
complex/JJ
pathogenesis/NN
,/,
and/CC
the/DT
disease/NN
mechanism/NN
is/VBZ
still/RB
unclear/JJ
;/:
however/RB
,/,
it/PRP
is/VBZ
widely/RB
accepted/VBN
that/IN
genetic/JJ
factors/NNS
could/MD
be/VB
important/JJ
contributors/NNS
to/TO
SLE/NN
[/(
23/CD
]/)
./.
====================
Accordingly/RB
,/,
several/JJ
lines/NNS
of/IN
evidence/NN
have/VBP
supported/VBN
that/DT
SLE/NN
may/MD
be/VB
explained/VBN
by/IN
genetic/JJ
factors/NNS
./.
====================
For/IN
instance/NN
,/,
the/DT
concordance/NN
rate/NN
of/IN
SLE/NN
in/IN
monozygotic/JJ
twins/NNS
(/(
24/CD
%/NN
to/TO
58/CD
%/NN
)/)
is/VBZ
higher/JJR
than/IN
the/DT
rate/NN
in/IN
dizygotic/JJ
twins/NNS
(/(
2/CD
%/NN
to/TO
5/CD
%/NN
)/)
,/,
and/CC
also/RB
,/,
the/DT
disease/NN
heritability/NN
is/VBZ
high/JJ
(/(
>/JJR
66/CD
%/NN
)/)
[/(
456/CD
]/)
./.
====================
A/DT
number/NN
of/IN
genome-wide/JJ
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
have/VBP
identified/VBN
novel/JJ
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
associated/VBN
with/IN
the/DT
risk/NN
of/IN
SLE/NN
,/,
such/JJ
as/IN
HLA/NN
,/,
PTPN22/NN
,/,
STAT4/NN
,/,
IRF5/NN
,/,
TNFAIP3/NN
,/,
BLK/NN
,/,
and/CC
BANK1/NN
,/,
in/IN
various/JJ
ethnic/JJ
groups/NNS
,/,
but/CC
most/JJS
of/IN
the/DT
GWASs/NNS
have/VBP
been/VBN
performed/VBN
in/IN
Caucasians/NNS
[/(
178910111213/CD
]/)
./.
====================
In/IN
Korea/NN
,/,
most/JJS
of/IN
the/DT
previously/RB
reported/VBD
SNPs/NNS
were/VBD
validated/VBN
by/IN
GWASs/NNS
,/,
and/CC
potentially/RB
East/JJ
Asian-specific/JJ
SNPs/NNS
,/,
such/JJ
as/IN
the/DT
SNPs/NNS
in/IN
ETS1/NN
,/,
IKZF1/NN
,/,
and/CC
SLC15A4/NN
,/,
were/VBD
also/RB
identified/VBD
[/(
141516/CD
]/)
./.
====================
Recently/RB
,/,
Bentham/NN
et/FW
al/JJ
./.
====================
[/(
12/CD
]/)
performed/VBN
a/DT
large-scale/JJ
GWAS/NN
with/IN
7,219/CD
cases/NNS
and/CC
15,991/CD
controls/NNS
in/IN
Europeans/NNS
and/CC
defined/VBN
43/CD
SLE/NN
loci/NNS
,/,
including/VBG
10/CD
new/JJ
loci/NNS
./.
====================
Among/IN
the/DT
SLE-associated/JJ
loci/NNS
in/IN
Bentham/NN
et/FW
al/JJ
./.
====================
[/(
12/CD
]/)
,/,
some/DT
of/IN
them/PRP
have/VBP
not/RB
been/VBN
replicated/VBN
in/IN
the/DT
Korean/JJ
population/NN
,/,
and/CC
others/NNS
were/VBD
replicated/VBN
but/CC
not/RB
concluded/VBN
to/TO
be/VB
associated/VBN
due/JJ
to/TO
a/DT
limited/JJ
sample/JJ
size/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
aimed/VBD
to/TO
replicate/VB
five/CD
SNPs/NNS
that/DT
were/VBD
not/RB
replicated/VBN
or/CC
concluded/VBN
to/TO
be/VB
association/NN
in/IN
Koreans/NNS
./.
====================
Study/NN
subjects/NNS
====================
All/DT
participants/NNS
were/VBD
of/IN
Korean/JJ
ancestry/NN
./.
====================
For/IN
the/DT
replication/NN
study/NN
,/,
656/CD
SLE/NN
patients/NNS
(/(
males/NNS
,/,
11/CD
;/:
females/NNS
,/,
645/CD
;/:
age/NN
[/(
mean/JJ
±/CD
SD/NN
]/)
,/,
33.7/CD
±/CD
12.1/CD
years/NNS
)/)
were/VBD
recruited/VBN
from/IN
the/DT
Rheumatology/NN
Center/JJ
at/IN
Seoul/JJ
St./NNP
Mary/JJ
's/POS
Hospital/JJ
,/,
The/DT
Catholic/JJ
University/JJ
of/IN
Korea/NN
,/,
South/DT
Korea/NN
./.
====================
All/DT
patients/NNS
had/VBD
been/VBN
diagnosed/VBN
as/IN
having/VBG
SLE/NN
according/VBG
to/TO
the/DT
American/NN
College/NN
of/IN
Rheumatology-revised/JJ
criteria/NNS
for/IN
SLE/NN
[/(
1718/CD
]/)
./.
====================
In/IN
addition/NN
,/,
the/DT
allele/NN
frequencies/NNS
for/IN
healthy/JJ
Korean/JJ
population/NN
as/IN
control/JJ
were/VBD
derived/VBN
from/IN
the/DT
Korea/NN
Reference/NN
Genome/NN
Database/NN
(/(
n=622/NN
)/)
./.
====================
This/DT
study/NN
was/VBD
performed/VBN
under/IN
the/DT
approval/JJ
of/IN
our/PRP$
institutional/JJ
review/NN
board/JJ
(/(
MC12TIMI0026/NN
)/)
./.
====================
SNP/NN
genotyping/VBG
====================
In/IN
this/DT
study/NN
,/,
we/PRP
selected/VBD
five/CD
SNPs/NNS
(/(
rs1801274/NN
in/IN
FCGR2A/NN
locus/NN
,/,
rs2286672/NN
in/IN
PLD2/NN
locus/NN
,/,
rs887369/NN
in/IN
CXorf21/NN
locus/NN
,/,
rs9782955/NN
in/IN
LYST/NN
,/,
and/CC
rs3794060/NN
in/IN
NADSYN1/NN
)/)
that/WDT
were/VBD
identified/VBN
to/TO
be/VB
associated/VBN
with/IN
SLE/NN
from/IN
a/DT
previous/JJ
GWAS/NN
[/(
12/CD
]/)
but/CC
have/VBP
not/RB
been/VBN
tested/VBN
in/IN
a/DT
Korean/JJ
population/NN
./.
====================
Five/CD
SNPs/NNS
were/VBD
genotyped/VBN
using/VBG
the/DT
TaqMan/NN
SNP/NN
Genotyping/JJ
Assay/NN
(/(
Applied/VBN
Biosystems/NNS
,/,
Foster/NN
City/NN
,/,
CA/NNP
,/,
USA/NN
)/)
for/IN
allelic/JJ
discrimination/NN
./.
====================
TaqMan/NN
polymerase/NN
chain/NN
reaction/NN
(/(
PCR/NN
)/)
and/CC
fluorescence/NN
measurements/NNS
were/VBD
performed/VBN
using/VBG
a/DT
ViiA/JJ
7/CD
Real-Time/NN
PCR/NN
System/NN
(/(
Applied/VBN
Biosystems/NNS
)/)
using/VBG
a/DT
384-well/JJ
plate/VBP
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
instructions/NNS
./.
====================
Statistical/JJ
analysis/NN
====================
Chi-square/JJ
test/NN
was/VBD
used/VBN
to/TO
estimate/VB
Hardy-Weinberg/JJ
equilibrium/NN
with/IN
the/DT
genotype/NN
data/NNS
of/IN
the/DT
SLE/NN
cases/NNS
and/CC
controls/VBZ
./.
====================
Significant/JJ
differences/NNS
in/IN
alleles/NNS
and/CC
genotype/NN
frequencies/NNS
between/IN
cases/NNS
and/CC
controls/VBZ
were/VBD
assessed/VBN
using/VBG
SPSS/NN
version/NN
22/CD
(/(
IBM/NN
Corp./NN
,/,
Armonk/NN
,/,
NY/NN
,/,
USA/NN
)/)
./.
====================
Odds/NNS
ratios/NNS
(/(
ORs/NNS
)/)
were/VBD
calculated/VBN
by/IN
case/NN
and/CC
control/NN
allele/NN
frequencies/NNS
with/IN
95/CD
%/NN
confidence/NN
intervals/NNS
(/(
CIs/NNS
)/)
./.
====================
The/DT
p-values/NNS
</JJR
0.05/CD
were/VBD
regarded/VBN
as/IN
statistically/RB
significant/JJ
./.
====================
Candidate/NN
SNP/NN
selection/NN
====================
Of/IN
the/DT
43/CD
SLE-associated/JJ
loci/NNS
identified/VBN
by/IN
Bentham/NN
et/FW
al/JJ
./.
====================
[/(
12/CD
]/)
,/,
we/PRP
narrowed/VBD
down/RB
the/DT
candidate/NN
SNPs/NNS
for/IN
this/DT
study/NN
per/IN
the/DT
following/VBG
criteria/NNS
:/:
SNPs/NNS
that/IN
had/VBD
not/RB
been/VBN
replicated/VBN
in/IN
the/DT
Korean/JJ
population/NN
,/,
SNPs/NNS
with/IN
a/DT
minor/JJ
allele/NN
frequency/NN
above/IN
5/CD
%/NN
in/IN
an/DT
East/JJ
Asian/JJ
population/NN
,/,
and/CC
SNPs/NNS
that/IN
were/VBD
replicated/VBN
in/IN
the/DT
Korean/JJ
population/NN
but/CC
inconclusive/JJ
owing/VBG
to/TO
the/DT
limited/JJ
sample/JJ
size/NN
./.
====================
Seven/CD
of/IN
the/DT
43/CD
SNPs/NNS
were/VBD
not/RB
replicated/VBN
in/IN
the/DT
Korean/JJ
population/NN
,/,
and/CC
five/CD
of/IN
them/PRP
showed/VBD
a/DT
minor/JJ
allele/NN
frequency/NN
above/JJ
5/CD
%/NN
in/IN
the/DT
East/JJ
Asian/JJ
population/NN
(/(
Supplementary/JJ
Table/JJ
1/CD
)/)
./.
====================
Therefore/RB
,/,
we/PRP
selected/VBD
the/DT
five/CD
SNPs/NNS
for/IN
a/DT
replication/NN
study/NN
in/IN
Koreans/NNS
(/(
rs1801274/NN
in/IN
FCGR2A/NN
locus/NN
,/,
rs2286672/NN
in/IN
PLD2/NN
locus/NN
,/,
rs887369/NN
in/IN
CXorf21/NN
locus/NN
,/,
rs9782955/NN
in/IN
LYST/NN
,/,
and/CC
rs3794060/NN
in/IN
NADSYN1/NN
)/)
(/(
Table/JJ
1/CD
)/)
./.
====================
Three/CD
of/IN
them/PRP
were/VBD
nonsynonymous/JJ
,/,
and/CC
the/DT
other/JJ
two/CD
were/VBD
intronic/JJ
SNPs/NNS
./.
====================
Association/NN
with/IN
SLE/NN
====================
A/DT
total/JJ
of/IN
656/CD
cases/NNS
and/CC
622/CD
controls/NNS
were/VBD
enrolled/VBN
and/CC
genotyped/VBD
to/TO
analyze/VB
the/DT
association/NN
with/IN
SLE/NN
./.
====================
Minor/CC
allele/NN
frequencies/NNS
of/IN
the/DT
five/CD
SNPs/NNS
in/IN
this/DT
study/NN
were/VBD
similar/JJ
to/TO
those/DT
in/IN
East/JJ
Asians/NNS
from/IN
1000/CD
Genomes/NNS
Database/NN
(/(
Table/JJ
2/CD
)/)
[/(
19/CD
]/)
,/,
suggesting/VBG
that/IN
this/DT
study/NN
group/NN
can/MD
represent/VB
the/DT
Korean/JJ
population/NN
and/CC
that/IN
our/PRP$
genotyping/VBG
was/VBD
reliable/JJ
./.
====================
We/PRP
performed/VBD
an/DT
association/NN
analysis/NN
with/IN
three/CD
different/JJ
genetic/JJ
models/NNS
:/:
allelic/JJ
,/,
dominant/JJ
,/,
and/CC
recessive/JJ
(/(
Table/JJ
3/CD
)/)
./.
====================
Of/IN
the/DT
five/CD
SNPs/NNS
,/,
rs1801274/NN
in/IN
FCGR2A/NN
was/VBD
significantly/RB
associated/VBN
with/IN
the/DT
risk/NN
of/IN
SLE/NN
in/IN
all/DT
three/CD
models/NNS
,/,
but/CC
the/DT
other/JJ
four/CD
SNPs/NNS
did/VBD
not/RB
show/VB
a/DT
significant/JJ
association/NN
./.
====================
Under/IN
allelic/JJ
model/NN
,/,
the/DT
minor/JJ
allele/NN
frequency/NN
of/IN
genotype/JJ
G/NN
in/IN
rs1801274/NN
was/VBD
significantly/RB
higher/JJR
in/IN
SLE/NN
patients/NNS
(/(
AF/NN
=/JJ
0.285/CD
)/)
than/IN
in/IN
controls/NNS
(/(
AF/NN
=/JJ
0.24/CD
)/)
(/(
OR/NN
,/,
1.26/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.06/CD
to/TO
1.50/CD
;/:
p/NN
=/JJ
0.01/CD
)/)
./.
====================
Also/RB
,/,
the/DT
dominant/JJ
model/NN
of/IN
minor/JJ
allele/NN
in/IN
rs1801274/NN
seems/VBZ
significantly/RB
associated/VBN
with/IN
SLE/NN
(/(
OR/NN
,/,
1.28/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.02/CD
to/TO
1.59/CD
;/:
p/NN
=/JJ
0.03/CD
)/)
./.
====================
Under/IN
recessive/JJ
model/NN
,/,
the/DT
genotype/NN
G/G/NN
of/IN
rs1801274/NN
was/VBD
significantly/RB
associated/VBN
with/IN
SLE/NN
(/(
OR/NN
,/,
1.55/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.01/CD
to/TO
2.39/CD
;/:
p/NN
=/JJ
0.046/CD
)/)
./.
====================
SLE/NN
is/VBZ
a/DT
complex/NN
autoimmune/JJ
disease/NN
caused/VBD
by/IN
complex/NN
interactions/NNS
between/IN
genetic/JJ
and/CC
environmental/JJ
components/NNS
[/(
420/CD
]/)
./.
====================
Its/PRP$
high/JJ
heritability/NN
and/CC
relatively/RB
higher/JJR
risks/NNS
in/IN
siblings/NNS
suggest/VBP
a/DT
genetic/JJ
contribution/NN
to/TO
the/DT
risk/NN
of/IN
SLE/NN
[/(
2122/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
aimed/VBD
to/TO
replicate/VB
five/CD
SNPs/NNS
that/IN
were/VBD
discovered/VBN
in/IN
Caucasians/NNS
[/(
12/CD
]/)
but/CC
not/RB
replicated/VBN
in/IN
Koreans/NNS
(/(
rs2286672/CD
in/IN
PLD2/NN
locus/NN
,/,
rs887369/RB
in/IN
CXorf21/NN
locus/NN
,/,
rs9782955/NN
in/IN
LYST/NN
,/,
and/CC
rs3794060/NN
in/IN
NADSYN1/NN
)/)
or/CC
replicated/VBN
in/IN
Koreans/NNS
(/(
rs1801274/NN
in/IN
FCGR2A/NN
locus/NN
)/)
with/IN
insufficient/JJ
sample/JJ
size/NN
to/TO
conclude/VB
any/DT
association/NN
./.
====================
Through/IN
a/DT
replication/NN
study/NN
with/IN
656/CD
cases/NNS
and/CC
622/CD
controls/NNS
,/,
rs1801274/NN
in/IN
FCGR2A/NN
was/VBD
found/VBN
to/TO
be/VB
significantly/RB
associated/VBN
with/IN
SLE/NN
in/IN
Koreans/NNS
./.
====================
However/RB
,/,
the/DT
other/JJ
four/CD
candidate/NN
SNPs/NNS
were/VBD
not/RB
replicated/VBN
in/IN
Koreans/NNS
./.
====================
The/DT
risk/NN
allele/NN
(/(
G/NN
)/)
of/IN
rs1801274/NN
in/IN
FCGR2A/NN
is/VBZ
a/DT
missense/NN
variant/JJ
that/DT
changes/NNS
a/DT
histidine/NN
to/TO
arginine/NN
[/(
23/CD
]/)
./.
====================
The/DT
human/JJ
Fcγ/NN
receptor/NN
(/(
FCGR/NN
)/)
gene/NN
family/NN
(/(
FCGR2A/NN
,/,
FCGR2B/NN
,/,
and/CC
FCGR2C/NN
)/)
is/VBZ
located/JJ
on/IN
chromosome/NN
1q23/NN
,/,
and/CC
it/PRP
is/VBZ
considered/VBN
to/TO
be/VB
associated/VBN
with/IN
the/DT
susceptibility/NN
to/TO
SLE/NN
[/(
2324/CD
]/)
./.
====================
Functionally/RB
,/,
human/JJ
Fcγ/NN
receptor/NN
is/VBZ
involved/VBN
in/IN
anti-inflammatory/JJ
regulation/NN
of/IN
immune/JJ
responses/NNS
./.
====================
Another/DT
important/JJ
role/NN
of/IN
human/JJ
Fcγ/NN
receptor/NN
is/VBZ
the/DT
clearance/NN
of/IN
immune/JJ
complexes/NNS
[/(
25/CD
]/)
./.
====================
Indeed/RB
,/,
FCGR/NN
polymorphisms/NNS
have/VBP
been/VBN
reported/VBN
to/TO
be/VB
associated/VBN
with/IN
the/DT
susceptibility/NN
to/TO
autoimmune/JJ
diseases/NNS
,/,
including/VBG
SLE/NN
[/(
262728/CD
]/)
./.
====================
A/DT
well-known/JJ
polymorphism/NN
is/VBZ
the/DT
missense/NN
variant/JJ
at/IN
amino/NN
acid/NN
131/CD
in/IN
FCGR2A/NN
,/,
which/WDT
decreases/VBZ
binding/NN
affinity/NN
to/TO
human/JJ
immunoglobulin/NN
G/NN
[/(
232829/CD
]/)
./.
====================
The/DT
homozygosity/NN
for/IN
R131/NN
,/,
being/VBG
regarded/VBN
as/IN
the/DT
low-binding/JJ
allele/NN
of/IN
FCGR2A/NN
,/,
is/VBZ
known/VBN
to/TO
be/VB
associated/VBN
with/IN
a/DT
1.30-fold/JJ
greater/JJR
risk/NN
for/IN
the/DT
development/NN
of/IN
SLE/NN
compared/VBN
with/IN
both/DT
of/IN
the/DT
other/JJ
genotypes/NNS
combined/JJ
[/(
3031/CD
]/)
./.
====================
Thus/RB
,/,
FCGR2A-R131/NN
may/MD
have/VB
potential/JJ
roles/NNS
in/IN
causing/VBG
defective/JJ
immune/JJ
complex/NN
clearance/NN
and/CC
increased/VBD
tissue/NN
deposition/NN
,/,
thereby/RB
leading/VBG
to/TO
accelerated/VBN
organ/NN
damage/NN
[/(
3032/CD
]/)
./.
====================
FCGR2A/DT
on/IN
phagocytic/JJ
cells/NNS
is/VBZ
a/DT
receptor/NN
for/IN
C-reactive/JJ
protein/NN
(/(
CRP/NN
)/)
and/CC
the/DT
serum/NN
amyloid/NN
P/NN
(/(
SAP/NN
)/)
component/NN
,/,
both/CC
acting/VBG
as/IN
opsonins/VBZ
for/IN
nuclear/JJ
antigens/NNS
[/(
3334/CD
]/)
,/,
and/CC
the/DT
binding/VBG
between/IN
receptor/NN
and/CC
CRP/NN
or/CC
SAP/NN
might/MD
be/VB
influenced/VBN
by/IN
polymorphisms/NNS
[/(
3035/CD
]/)
,/,
because/IN
there/EX
is/VBZ
a/DT
dose-response/JJ
characteristic/JJ
between/IN
FCGR-2A-R/H131/NN
and/CC
the/DT
risk/NN
of/IN
SLE/NN
,/,
with/IN
an/DT
escalation/NN
of/IN
SLE/NN
risk/NN
between/IN
RR/NN
homozygotes/NNS
and/CC
RH/JJ
heterozygotes/NNS
[/(
303132/CD
]/)
./.
====================
Vigato-Ferreira/NN
et/FW
al/JJ
./.
====================
[/(
27/CD
]/)
examined/VBN
the/DT
allelic/JJ
distribution/NN
of/IN
FCGR2A/NN
in/IN
a/DT
Brazilian/JJ
population/NN
(/(
157/CD
SLEs/NNS
and/CC
160/CD
controls/NNS
)/)
./.
====================
They/PRP
found/VBN
that/IN
two/CD
polymorphisms/NNS
of/IN
FCGR2A/NN
were/VBD
associated/VBN
with/IN
SLE/NN
(/(
FCGR2A-R-131/NN
and/CC
RR-131/NN
)/)
,/,
noting/VBG
that/DT
the/DT
FCGR2A-H-131/NN
allele/NN
was/VBD
associated/VBN
with/IN
the/DT
susceptibility/NN
to/TO
arthritis/NN
and/CC
anti-DNA/JJ
antibodies/NNS
[/(
27/CD
]/)
./.
====================
In/IN
the/DT
meta-analysis/NN
performed/VBN
by/IN
Li/NN
et/FW
al/JJ
./.
====================
[/(
28/CD
]/)
,/,
the/DT
FCGR2A-R/H131/NN
variant/JJ
was/VBD
associated/VBN
with/IN
the/DT
development/NN
of/IN
SLE/NN
in/IN
Asians/NNS
both/CC
at/IN
the/DT
allele/NN
and/CC
genotype/NN
level/NN
./.
====================
Low/JJ
copy/NN
number/NN
of/IN
FCGR/NN
genes/NNS
,/,
including/VBG
FCGR2A-RR-131/NN
,/,
FCGR3B/NN
,/,
and/CC
the/DT
2B.4/CD
haplotype/NN
of/IN
FCGR2B/NN
,/,
has/VBZ
also/RB
been/VBN
reported/VBN
to/TO
be/VB
associated/VBN
with/IN
the/DT
susceptibility/NN
to/TO
SLE/NN
[/(
26/CD
]/)
./.
====================
Other/JJ
studies/NNS
also/RB
reported/VBD
the/DT
association/NN
between/IN
FCGR2A/NN
and/CC
SLE/NN
nephritis/NN
in/IN
the/DT
Korean/JJ
population/NN
[/(
36373839/CD
]/)
,/,
demonstrating/VBG
that/IN
the/DT
FCGR2A/NN
H131R/NN
missense/NN
variation/NN
is/VBZ
presented/VBN
as/IN
a/DT
risk/NN
allele/NN
of/IN
SLE/NN
and/CC
SLE/NN
nephritis/NN
./.
====================
However/RB
,/,
the/DT
association/NN
was/VBD
hard/RB
to/TO
conclude/VB
because/IN
of/IN
the/DT
lack/NN
of/IN
power/JJR
due/JJ
to/TO
the/DT
limited/JJ
small/JJ
sample/NN
size/NN
(/(
73/CD
to/TO
300/CD
patients/NNS
)/)
./.
====================
In/IN
conclusion/NN
,/,
in/IN
this/DT
study/NN
,/,
we/PRP
performed/VBD
a/DT
replication/NN
study/RB
of/IN
five/CD
SNPs/NNS
,/,
previously/RB
known/VBN
to/TO
be/VB
associated/VBN
with/IN
SLE/NN
but/CC
not/RB
replicated/VBN
in/IN
Koreans/NNS
,/,
with/IN
a/DT
relatively/RB
large/JJ
amount/IN
of/IN
samples/NNS
,/,
demonstrating/VBG
that/IN
rs1801274/NN
in/IN
FCGR2A/NN
shows/VBZ
a/DT
nominally/RB
significant/JJ
association/NN
with/IN
SLE/NN
,/,
but/CC
the/DT
other/JJ
four/CD
SNPs/NNS
appear/VBP
to/TO
have/VB
no/DT
association/NN
in/IN
the/DT
Korean/JJ
population/NN
./.
====================
Our/PRP$
result/NN
is/VBZ
supportive/JJ
that/DT
FCGR/NN
polymorphisms/NNS
may/MD
play/VB
important/JJ
roles/NNS
in/IN
the/DT
susceptibility/NN
to/TO
SLE/NN
in/IN
diverse/JJ
populations/NNS
,/,
including/VBG
Koreans/NNS
./.
====================
SNP/NN
information/NN
for/IN
allele/NN
genotyping/VBG
====================
Alternative/JJ
allele/NN
frequencies/NNS
of/IN
five/CD
SNPs/NNS
in/IN
patients/NNS
with/IN
SLE/NN
and/CC
controls/VBZ
====================
Genotypic/JJ
association/NN
between/IN
each/DT
SNP/NN
and/CC
SLE/NN
risk/NN
in/IN
Korean/JJ
SLE/NN
patients/NNS
and/CC
healthy/JJ
controls/NNS
====================
